Everything You need to know about the GLP-1 Bridge Program

Historically, Medicare has not permitted Part D plans to cover drugs like Wegovy and Zepbound for a non-diabetes diagnosis unless it was tied to certain other chronic conditions. The GLP‑1 Bridge is a short‑term Medicare program that expands access to weight‑loss medications outside of traditional drug coverage.

On July 1, 2026, Medicare launches this temporary national program. It will run through December 31, 2027.

Because this program operates outside of Part D, insurance companies do not control access or pricing. Additionally, anytime these medications are purchased through the bridge program, the amount paid does not count towards the member’s Medicare drug plan’s max-out-of-pocket limit, which is $2,100 for all 2026 plans.

Medicare is offering these medications at a highly subsidized, standardized monthly cost at $50/month.

A GLP-1 drug medication mimics a natural hormone in your body.

It helps to regulate blood sugar, appetite, and digestion—which is why they’re effective for diabetes management, and by extension, weight loss.

Those who are already have coverage for GLP-1 medications under Part D are not eligible to participate. The program is not intended to duplicate coverage. It is intended to fill a “gap” in coverage for those who are not currently eligible for the medication due to Part D limitations. The bridge program is aimed at those who do not have diabetes and cannot currently access the drugs.

Eligibility criteria include:

• Being a Medicare beneficiary with Part D
• meeting medical criteria such as a certain BMI threshold and/or certain medical issues
• receiving a physician’s prescription through the bridge program
• obtaining approval by Medicare
• filling the prescription through a participating pharmacy
• paying the requisite copay (“extra help” recipients do not appear to receive any cost share assistance through this program)

GLP‑1 drugs can cost $10,000–$15,000 per year per patient. When filled under a traditional Part D plan, a beneficiary will pay their plan’s deductible, then the copay or coinsurance for the drug. The max drug deductible for 2026 is $615 for all Part D plans. GLP-1 drugs are typically listed as a Tier 3 on most Part D plans and carry a coinsurance of around 17% to 25% or a fixed copay depending on the plan. A member will owe these expenses until the $2,100 max is hit (it includes what the drug plan pays toward the drug as well).

Unlike traditional Medicare drug coverage, where insurers control formularies and pricing, the GLP‑1 Bridge is administered directly by the federal government. This effectively removes insurance carriers from both the approval process and cost structure. It also allows Medicare to bypass their own restrictions related to these drugs.

When someone participates in the bridge program, they pay the $50 copay, and the government picks up the rest of the tab.

The government is testing whether covering obesity treatment saves money over-all. While the medications may be expensive, if the long‑term result of covering these medications leads to lower cost and better health outcomes, it will may be worth changing the Part D regulations to allow them to be covered for weight loss purposes.  

The bridge program allows the government

• to bypass its own legal limitations
• to control all aspects of the “test” by keeping the cost structure under Medicare’s control
• to gather real-world data from patients to determine the program’s effectiveness

If the program is “successful,” look for Medicare to adjust the Part D rules to allow insurance companies to cover GLP-1 drugs in the future. 

Medicare primarily covers acute healthcare, meaning you have to have a health issue with a clear or definable onset of symptoms. Chronic conditions, like obesity, develop over years and are often considered co-morbidities. 

If Medicare can answer “yes” to – Is it worth paying more upfront for prevention if it lowers the total cost of care over time? – then it is a net win for everyone.

This program may signal a shift in the way Medicare approaches prevention and co-morbidities.

In short, the program

• expands access where none existed previously
• simplifies and reduces pricing significantly
• treats obesity as a legitimate medical condition
• may improve long-term medical outcomes
• depends on real-world data to back up decision making

As with all improvements, there are also limitations, drawbacks and potential pitfalls. 

Some of these include:

• the program is temporary and may not ultimately lead to any changes
• expenses paid by a member do not count to Part D out-of-pocket limits
• eligibility is limited to certain criteria
• there is no competition since it is controlled by the government
• taxpayers are footing a sizable bill for this Medicare experiment
• the artificially low pricing for these medications is temporary and will certainly cost more when the government ceases to pay the bill
• not all medications will be covered

Learn more about the GLP–1 bridge at: 

https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge 

and 

https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf.